- Ofatumumab updates on trials, anticipated timelines and clinical experience
- Pre-clinical combination treatment data for daratumumab
- New data on the HuMax-TF Antibody-Drug Conjugate (ADC) program
- Update on next generation bispecifics platform
Copenhagen, Denmark; January 20, 2011 –Genmab A/S (OMX: GEN) will present a comprehensive update on its clinical pipeline, pre-clinical portfolio and next generation antibody technologies at its R&D Day to be held today at its research facilities in Utrecht, the Netherlands. Today’s presentations will be available via live webcast at 1:30PM CET at www.genmab.com.
Highlights will include:
- Discussion of ongoing ofatumumab trials including clinical study initiation and data timelines. An interim analysis of the Phase II study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed/refractory diffuse large B cell lymphoma (DLBCL) has been conducted in collaboration with GlaxoSmithKline (GSK).
“We recently performed a pre-planned interim analysis for futility of our Phase II ofatumumab study in relapsed or refractory DLBCL. The analysis showed that the pre-specified minimum response rate was met or exceeded, clearly warranting continued recruitment into the study and we hope that we will be able to present primary endpoint data from this important study later this year,” said Klaus Edvardsen, Project Physician leader for ofatumumab at GSK.
-
A clinician’s perspective on ofatumumab. Dr.Myron Czuczman, Professor of Medicine, State University of New York at Buffalo, and Chief, Lymphoma/Myeloma Service at Roswell Park Cancer Institute, will present his experience to date of treating cancer patients with ofatumumab.
-
Pre-clinical data from the daratumumab program. In pre-clinical studies, daratumumab has shown enhanced efficacy in killing multiple myeloma cells in combination with existing chemotherapy regimens. Data from the Phase I/II study is expected in 2011 and combination studies are being planned.
-
Updates on the zalutumumab, RG4930 and RG1512 programs. A Phase II study of RG1512 in cardiovascular disease was initiated by Genmab’s partner, Roche, in December 2010.
-
Pre-clinical portfolio update includingearly encouraging in vitro and in vivo data from the HuMax-TF™ ADC program in collaboration with Seattle Genetics.
- Exploration of Genmab’s proprietary, next-generation antibody technologies. Our bispecifics platform, DuoBody™, is uniquely based on a natural process that efficiently generates stable human antibodies that have the ability to bind two targets in a single molecule and may remain in the body as long as regular human antibodies. This novel format may represent a next wave in therapeutic antibody development, leading to increased efficacy and improved specificity of future antibody therapies.
“Genmab’s success is dependent upon our ability to develop and access innovative technologies and create differentiated therapeutic products,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “I’m delighted to have the opportunity to share our progress in these areas and to showcase our state-of-the-art research and development facilities here in Utrecht.”
Today’s presentation will also be available by webcast replay approximately one hour following conclusion of the event.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab’s world class discovery and development teams are using cutting-edge technology to create and develop products to address unmet medical needs. Our primary goal is to improve the lives of patients who are in urgent need of new treatment options. For more information on Genmab’s products and technology, visit www.genmab.com.
Contact:
Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com
This Press Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s Annual Report, which is available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Press Release nor to confirm such statements in relation to actual results, unless required by law.
Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax-EGFr™;HuMax-IL8™;HuMax-TAC™;HuMax-HepC™; HuMax-CD38™; HuMax-TF™; HuMax-Her2™; HuMax-Wnt™; HuMax-cMet™; DuoBody™ and UniBody®are all trademarks of Genmab A/S. Arzerra®is a trademark of GlaxoSmithKline.
Investor News no. 01
CVR no. 2102 3884
